WallStSmart

Vuzix Corp Cmn Stk (VUZI)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 4022% more annual revenue ($258.90M vs $6.28M). VUZI leads profitability with a 0.0% profit margin vs -15.5%. ZEPP earns a higher WallStSmart Score of 38/100 (F).

VUZI

Avoid

26

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 6.7Quality: 7.0
Piotroski: 5/9Altman Z: -4.27

ZEPP

Hold

38

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

VUZIUndervalued (+43.2%)

Margin of Safety

+43.2%

Fair Value

$4.35

Current Price

$2.84

$1.51 discount

UndervaluedFair: $4.35Overvalued
ZEPPUndervalued (+48.8%)

Margin of Safety

+48.8%

Fair Value

$46.82

Current Price

$18.43

$28.39 discount

UndervaluedFair: $46.82Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

VUZI2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
76.3%10/10

Revenue surging 76.3% year-over-year

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

VUZI4 concerns · Avg: 3.5/10
Price/BookValuation
9.5x4/10

Trading at 9.5x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$236.17M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

ZEPP4 concerns · Avg: 2.3/10
Market CapQuality
$270.28M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Free Cash FlowQuality
$-26.48M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : VUZI

The strongest argument for VUZI centers on Revenue Growth, Debt/Equity. Revenue growth of 76.3% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : VUZI

The primary concerns for VUZI are Price/Book, EPS Growth, Market Cap.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

VUZI is growing revenue faster at 76.3% — sustainability is the question.

VUZI generates stronger free cash flow (-6M), providing more financial flexibility.

Monitor CONSUMER ELECTRONICS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (38/100 vs 26/100) and 43.0% revenue growth. VUZI offers better value entry with a 43.2% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Vuzix Corp Cmn Stk

TECHNOLOGY · CONSUMER ELECTRONICS · USA

Vuzix Corporation designs, manufactures, markets and sells augmented reality (AR) computing and display devices for consumer and business markets in North America, Asia-Pacific, Europe, and internationally. The company is headquartered in West Henrietta, New York.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?